Genetic test could aid quest to reveal causes of rare diseases

December 17, 2019

The causes of rare diseases could be uncovered using an approach created to identify genetic mutations that trigger a muscle-wasting condition, a study suggests.

Researchers have devised a way to pinpoint defective genes that are linked to a rare form of muscular dystrophy, which causes muscle weakening and heart problems.

The approach could help doctors perform a faster and cheaper diagnosis of the condition - called Emery-Dreifuss muscular dystrophy, or EDMD.

It could also be adapted to screen for gene mutations involved in other rare diseases, researchers say.

Discovering the cause of rare conditions can be challenging. Robust genetic screening tests are difficult when only a relatively small number of people are affected.

Previous research has shown that mutations in six different genes cause EDMD, which affects around one in 100,000 people worldwide.

However, these mutations are found in less than half of people diagnosed with the disease, indicating that other genes can also trigger it, researchers say.

Researchers from the University of Edinburgh designed a new multi-stage sequencing approach to discover other genetic mutations that might lead to EDMD.

They initially identified more than 300 genes that could be involved, including ones linked to other forms of muscular dystrophy and those that perform a similar function to the genes known to cause EDMD.

By analysing these alongside the genetic code of 56 people from the UK and Germany diagnosed with EDMD, the team identified more than 20 new mutations that appear to cause the condition. These are likely most of the remaining genes linked to EDMD, researchers say.

The study, published in the journal EBioMedicine, was funded by Wellcome, Muscular Dystrophy UK, the Medical Research Council, and the European Union's Seventh Framework Programme.

Professor Eric Schirmer, of the University of Edinburgh's School of Biological Sciences, who led the study, said: "As well as helping to identify mutations in rare diseases, using our approach in initial NHS screening would also save money and help spot misdiagnoses. This is particularly important as it can take many years to get a clear diagnosis of EDMD."

Dr Kate Adcock, Director of Research and Innovation at Muscular Dystrophy UK, said: "We know that many people with neuromuscular conditions are living without a genetic diagnosis. This research could pave the way to help people to get a diagnosis earlier. This will help people to manage their condition thereby helping to provide a better quality of life."

University of Edinburgh

Related Muscular Dystrophy Articles from Brightsurf:

Using CRISPR to find muscular dystrophy treatments
A study from Boston Children's Hospital used CRISPR-Cas9 to better understand facioscapulohumeral muscular dystrophy (FSHD) and explore potential treatments by systematically deleting every gene in the genome.

Duchenne muscular dystrophy diagnosis improved by simple accelerometers
Testing for Duchenne muscular dystrophy can require specialized equipment, invasive procedures and high expense, but measuring changes in muscle function and identifying compensatory walking gait could lead to earlier detection.

New therapy targets cause of adult-onset muscular dystrophy
The compound designed at Scripps Research, called Cugamycin, works by recognizing toxic RNA repeats and destroying the garbled gene transcript.

Gene therapy cassettes improved for muscular dystrophy
Experimental gene therapy cassettes for Duchenne muscular dystrophy have been modified to deliver better performance.

Discovery points to innovative new way to treat Duchenne muscular dystrophy
Researchers at The Ottawa Hospital and the University of Ottawa have discovered a new way to treat the loss of muscle function caused by Duchenne muscular dystrophy in animal models of the disease.

Extracellular RNA in urine may provide useful biomarkers for muscular dystrophy
Massachusetts General Hospital researchers have found that extracellular RNA in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.

Tamoxifen and raloxifene slow down the progression of muscular dystrophy
Steroids are currently the only available treatment to reduce the repetitive cycles of inflammation and disease progression associated with functional deterioration in patients with muscular dystrophy (MD).

Designed proteins to treat muscular dystrophy
The cell scaffolding holds muscle fibers together and protects them from damage.

Gene-editing alternative corrects Duchenne muscular dystrophy
Using the new gene-editing enzyme CRISPR-Cpf1, researchers at UT Southwestern Medical Center have successfully corrected Duchenne muscular dystrophy in human cells and mice in the lab.

GW researcher finds genetic cause of new type of muscular dystrophy
George Washington University & St. George's University of London research, published in The American Journal of Human Genetics, outlines a newly discovered genetic mutation associated with short stature, muscle weakness, intellectual disability, and cataracts, leading researchers to believe this is a new type of congenital muscular dystrophy.

Read More: Muscular Dystrophy News and Muscular Dystrophy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to